Madrigal Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resme…
Biotechnology
US, West Conshohocken [HQ]

Ratios

15 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
100.00 100.00 100.00 100.00 - - - - - - - - - - - - - - - - - - - - - -
Profit Margin
54.83 -253.10 -624.74 -42,714.29 - - - - - - - - - - - - - - - - - - - - - -
Operating Margin
54.98 -249.26 -599.05 -41,456.46 - - - - - - - - - - - - - - - - - - - - - -
EPS Growth
184.87 -139.84 -8.16 -5.27 -20.25 31.16 -1,211.43 98.74 49.90 12.60 -113.06 -170.19 -14.09 -19.82 -14.43
Return on Assets (ROA)
161.70 -69.30 -111.95 -60.95 -94.74 -85.58 -100.70 -64.03 -16.20 -6.76 -16.47 -68.80 -88.20 -82.55 -58.33
Return on Equity (ROE)
317.48 -159.58 -320.70 -83.65 -183.72 -132.28 -136.23 -72.47 -17.09 -6.88 -17.48 -82.28 -122.93 -151.64 -92.18
Return on Invested Capital (ROIC)
288.63 -104.31 -144.59 -69.67 -120.79 -106.21 -122.80 -69.28 -17.23 -10.58 -19.74 -83.81 -122.76 -120.31 -72.98
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
4.21 22.00 39.34 12.04 24.58 13.81 6.82 - - - - - - 0.15 0.27 0.29 13.76 18.11
Debt/Equity
8.27 50.66 112.68 16.52 47.66 21.35 9.23 - - - - - - 0.16 0.33 0.41 25.28 28.62
Debt/EBITDA
-49.97 55.53 30.54 114.80 28.83 38.57 45.28 160.56 597.36 1,189.02 48.46 25.75 14.63 96.66 -4.55
Debt/Capitalization
7.64 33.62 52.98 14.18 32.28 17.59 8.45 - - - - - - 0.16 0.33 0.40 20.18 22.25
Interest Debt per Share USD
2.45 10.81 13.79 8.40 12.84 5.73 33.40 0.22 0.05 0.52 0.76 0.05 0.05 3.14 6.89
Debt Growth
-80.33 477.10 39.97 -25.51 88.66 -40.57 -66.56 -100.00 - - - - - - 16.27 1.40 6,159.85 134.90
Liquidity
Current Ratio
270.65 307.84 265.95 431.68 286.40 321.62 381.02 858.48 1,909.81 5,746.10 1,751.68 612.50 353.58 311.81 537.57
Quick Ratio
268.11 305.26 262.25 428.34 284.03 316.26 374.26 1,288.62 2,331.68 10,777.56 1,747.10 610.32 351.84 309.57 534.91
Cash Ratio
268.11 187.08 198.54 347.07 150.56 149.00 196.57 843.73 1,904.98 5,728.54 185.82 116.00 47.20 286.08 84.28
Operating Cash Flow Ratio
-100 -200 -300 -200 -200 -200 -400 -300 -200 -300 -100 -300 -200 -100 -200
Turnover
Inventory Turnover
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Receivables Turnover
- - 12,761.21 - - - - - - - - - - - - - - - - - - - - - - - - - -
Payables Turnover
- - - - - - - - - - - - - - - - - - - - 9.51 46.31 1.89 1.96 1.88
Asset Turnover
294.92 27.38 17.92 0.14 - - - - - - - - - - - - - - - - - - - - - -
Coverage
Interest Coverage
25,417.95 -6,484.71 -2,332.24 -3,295.89 -3,325.45 -3,798.69 -6,372.29 -2,167.01 -5,745.88 -530.34 -861.50 - - - - -7,405.93 -2,993.20
Asset Coverage
1,600 300 100 700 300 500 1,100 - - - - - - 61,700 30,600 24,700 400 400
Cash Flow Coverage (CFGR)
-1,300.82 -321.16 -284.12 -436.50 -330.84 -567.56 -1,536.43 - - - - - - -6,157.40 -20,045.93 -23,076.16 -450.70 -279.49
EBITDA Coverage
26,900 -6,100 -2,200 -3,200 -3,300 -3,700 -6,300 -2,100 -5,700 -500 -800 - - - - -7,300 -2,900
Dividend Coverage
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Time Interest Earned (TIE)
200 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Market Prospects
Dividend Yield
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Yield
46.12 -15.17 -21.50 -11.72 -24.25 -33.01 -3,278.01 -34.03 -2.77 -1.97 -5.19 -11.50 -17.21 -6.02 -8.64
Price/Earnings (P/E)
216.81 -659.33 -465.19 -853.45 -412.36 -302.91 -3.05 -293.88 -3,607.76 -5,083.31 -1,926.34 -869.72 -581.22 -1,661.82 -1,157.29
Price/Book (P/B)
688.33 1,052.14 1,491.87 713.88 757.60 400.69 4.16 212.99 616.68 349.67 336.71 715.59 714.50 2,519.93 1,066.77
Price/Sales (P/S)
118.87 1,668.79 2,906.24 364,546.52 - - - - - - - - - - - - - - - - - - - - - -
Price/Cash Flow (P/CF)
-639.57 -646.70 -465.98 -989.90 -480.44 -330.68 -2.93 -440.43 -5,036.35 -6,538.93 -3,369.71 -1,089.87 -761.86 -2,212.10 -1,333.61
End of MDGL's Analysis
CIK: 1157601 CUSIP: 558868105 ISIN: US5588681057 LEI: - UEI: -
Secondary Listings
MDGL has no secondary listings inside our databases.